Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an announcement.
Xspray Pharma has published its Annual Report 2025, providing shareholders and stakeholders with a comprehensive overview of the company’s performance, strategy, market environment, and governance during the year. The report outlines the firm’s technology platform, product portfolio, commercialization plans, sustainability work, and detailed financial statements for both the group and parent company, offering transparency into its operational and financial development.
The annual report also includes discussion of Xspray Pharma’s strategic positioning in the oncology market, its corporate governance structure, and information on its board, executive management, and share. By consolidating financial data, governance disclosures, and strategic narratives in a single document, the company aims to inform investors and other stakeholders about its progress, risk profile, and long-term value-creation ambitions.
The most recent analyst rating on (SE:XSPRAY) stock is a Hold with a SEK25.00 price target. To see the full list of analyst forecasts on Xspray Pharma AB stock, see the SE:XSPRAY Stock Forecast page.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing cancer therapies, leveraging its proprietary HyNap technology platform to create improved formulations of existing oncology drugs. The company’s operations span research, product development, and commercialization activities within the global oncology market.
Average Trading Volume: 47,915
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.15B
For detailed information about XSPRAY stock, go to TipRanks’ Stock Analysis page.